Oligonucleotide CDMO Market

The report "Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA), Application (Therapeutic, Research, Diagnostics), End User (Pharma, Biotech), Region, Competition - Global Forecast to 2031" is expected to reach USD 11.14 billion in 2031 from USD 3.88 billion in 2026, at a CAGR of 23.5% during the forecast period.

Browse 400 market data Tables and 50 Figures spread through 300 Pages and in-depth TOC on "Oligonucleotide CDMO Market by Service (Contract Manufacturing (Clinical, Commercial), Development), Type (ASO, SiRNA), Application (Therapeutic, Research, Diagnostics), End User (Pharma, Biotech), Region, Competition - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/oligonucleotide-cdmo-market-227700087.html

The oligonucleotide CDMO market is growing significantly, driven by expanding oligonucleotide development pipelines, increased outsourcing of manufacturing, rising demand for scalable GMP production, and greater use of specialized CDMO services. Pharmaceutical and biotechnology companies increasingly rely on CDMOs for process development, oligonucleotide synthesis and purification, analytical testing, and GMP manufacturing. The shift toward integrated CDMO services is further supporting market expansion, particularly as sponsors advance oligonucleotide programs from preclinical development to clinical and commercial stages. However, the market continues to face challenges, including complex synthesis and purification requirements, specialized manufacturing infrastructure, stringent quality controls, and difficulties scaling production while maintaining purity, yield, consistency, and cost efficiency.

By service type, the contract development segment will be the fastest-growing segment during the forecast period for the oligonucleotide CDMO market.

By service type, the oligonucleotide CDMO market is segmented into contract manufacturing, contract development, and other services. Contract development will be the fastest-growing segment over the forecast period. This growth is driven by increasing outsourcing of oligonucleotide production as programs advance toward clinical and commercial stages. CDMOs provide GMP synthesis, purification, scale-up, and quality control to meet growing production requirements. The commercial stage contributes significantly, as approved oligonucleotide therapies require a reliable, long-term API supply. Clinical-stage programs also drive demand for scalable manufacturing to support later-stage trials. The growing need for specialized manufacturing infrastructure and consistent product quality further supports the dominance of contract manufacturing.

By application, the therapeutic application segment held the largest share of the oligonucleotide CDMO market in 2025.

By application, the oligonucleotide CDMO market is segmented into therapeutic, research, and diagnostic applications. In 2025, therapeutic applications accounted for the largest market share. This is primarily due to the growing development of oligonucleotide-based therapeutics and increasing demand for GMP manufacturing. Pharmaceutical and biotechnology companies are increasingly outsourcing synthesis, purification, analytical testing, and commercial-scale production to specialized CDMOs. The advancement of ASO and siRNA programs across clinical and commercial stages is further increasing demand for scalable manufacturing capabilities. The growing complexity of therapeutic oligonucleotides and the need for consistent quality during scale-up also support the leading position of therapeutic applications in the market.

By region, North America accounted for the largest share of the market in 2025.

In 2025, North America held the largest share of the oligonucleotide CDMO market. This position is supported by a strong concentration of pharmaceutical and biotechnology companies with active oligonucleotide pipelines and established manufacturing infrastructure. The region has developed capabilities across oligonucleotide synthesis, purification, analytical development, and GMP manufacturing. Rising demand for clinical and commercial manufacturing capacity is further supporting regional growth. Advancements in ASO, siRNA, and other oligonucleotide programs are increasing the need for scalable production and specialized manufacturing services. The region also benefits from established clinical development capabilities and a mature regulatory environment that supports the development and manufacturing of oligonucleotide therapeutics. Increasing outsourcing by sponsors seeking specialized manufacturing infrastructure is expected to further strengthen North America's position in the market.

Leading players in the market include Agilent Technologies, Inc. (US), Bachem (Switzerland), WuXi AppTec, Thermo Fisher Scientific Inc. (US), and ST Pharm (South Korea), among others.

Don’t miss out on business opportunities in Oligonucleotide CDMO Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com